On Tuesday, Silicon Valley darling Snowflake went public at $120 per share… more than double the $12.4 billion valuation the cloud data company reached in a private funding round earlier this year. And then, it more than doubled in price on its IPO day.
It’s just the latest sign of the IPO craze in the United States. But while we’re seeing tech IPOs like Snowflake make splashes, this past week, Teeka revealed the hottest IPO market is actually biotech/biopharma.
According to research firm Pitchbook, venture capitalists have raised over $5.5 billion for biopharma companies in Q2 2020. That’s their largest quarter in history.
Already, we’ve seen biotech IPOs like Inovio Pharmaceuticals, Moderna, and Seres Therapeutics soar 293%, 159%, and 687%, respectively.
So far in 2020, the average pre-IPO deal has returned over 22,000% on IPO day… But if you had waited and didn’t get in until the IPO shares became available… that 22,000% return shrinks to just 36%.
So you can see if you’re not in before the IPO, you’re losing out on what could be life-changing profits. The best part is that there are multiple ways to play this class. And this past week, Teeka identified his top methods to play this trend.
|
|
|
|
|
Regards,
Chaka Ferguson
Managing Editor, Palm Beach Daily
P.S. While Wall Street was busy lying to you last year, pumping up their “hot” IPOs like Uber, Pinterest, and Lyft (which sank almost 75%)… tech legend and PBRG friend Jeff Brown was playing a different game.
Jeff honed in on tiny “penny IPOs.” And on September 23 at 8 p.m. ET, he’ll reveal this secret class of IPOs that go public almost every week… that anyone can buy… and that are 100–300x cheaper than overhyped stocks like Uber and Zoom.